Professor, University of Cincinnati
Dr. Ahn is Mitchell P. Kartalia Chair Professor of Engineering in the School of Electronics and Computing Systems at the University of Cincinnati. He is currently Co-Director of the Ohio Center for Microfluidic Innovation (OCMI) at the University of Cincinnati, which was funded from the Ohio 3rd Frontier Wright Projects Program. He obtained his Ph.D. degree in Electrical Engineering from Georgia Institute of Technology in 1993. Prior to joining the University of Cincinnati, he worked as a Post-Doctoral Fellow at IBM T. J. Watson Research Center, NY, USA. Since joining the University of Cincinnati in 1994, he has successfully initiated and established an excellent Microfluidics and BioMEMS program (www.biomems.uc.edu) at the University of Cincinnati, and he has been recognized internationally as one of the pioneers in the BioMEMS and lab-on-a-chip fields. One of his key inventions and pioneering contributions includes the new concept of “smart polymer lab-on-a-chip” for the point-of-care testing (POCT) clinical diagnostics and “lab-on-a-tube” for the neurosurgical diagnostics of traumatic brain injury (TBI). He has published over ~350 journal and peer-reviewed conference papers, and chaired numerous international conferences and steering committees. His research interests include the design, simulation, fabrication and characterization of BioMEMS devices, microfluidic device and systems, biosensors and biochips, lab-on-a-chips, in vitro diagnostics (IVD), and point-of-care clinical diagnostics or neurosurgical monitoring. He received the Scientific Leadership Award at the 4th Annual BioMEMS and Biomedical Nanotechnology World in 2003 and received the Best Journal Paper Award of the IEEE Sensor Journal in 2009. He is currently serving as an Editor of the IEEE/ASME Journal of Microelectromechanical Systems (JMEMS), and Editorial Boards of the Journal of Micromechanics and Microengineering (JMM), Journal of Microfluidics and Nanofluidics, and Current Nanoscience. He is currently a Fellow at the Institute of Physics. He was the founder of Siloam Biosciences Inc. (www.siloambio.com) in Cincinnati, Ohio, USA.
Senior Consultant, NCN Enterprises
Dr. Nelson received his BS in Chemistry from The California Institute of Technology in 1976 and his PhD in Chemistry from the University of California at San Diego in 1982. He joined Gen-Probe (a leading molecular diagnostics company) in 1985, where over his 27 year tenure held positions of increasing responsibility, culminating in the role of Senior Director of Discovery Research. Dr. Nelson has extensive experience in the development of technology for FDA-regulated molecular diagnostic products. He is also an expert in Next Generation Sequencing, including direct experience with Illumina, Ion Torrent & Pacific Biosciences platforms. He also has a proven track record in innovation, as well as the associated reduction to practice and implementation. As an inventor or co-inventor on 26 issued U.S. patents, and more than 100 issued and pending patents world-wide, he played a key role in the commercialization of multiple technologies, many of which are core to Gen-Probe products that generate >$500MM in annual revenue. He also has broad expertise and experience in intellectual property protection. Dr. Nelson now owns his own consulting business, NCN Enterprises.
Professor, Dana Farber Cancer Institute
John Quackenbush received his PhD in 1990 in theoretical physics from UCLA working on string theory models. Following two years as a postdoctoral fellow in physics, Dr. Quackenbush applied for and received a Special Emphasis Research Career Award from the National Center for Human Genome Research to work on the Human Genome Project. He spent two years at the Salk Institute and two years at Stanford University working at the interface of genomics and computational biology. In 1997 he joined the faculty of The Institute for Genomic Research (TIGR) where his focus began to shift to understanding what was encoded within the human genome. Since joining the faculties of the Dana-Farber Cancer Institute and the Harvard School of Public Health in 2005, his work has focused on the use of genomic data to reconstruct the networks of genes that drive the development of diseases such as cancer and emphysema.